SCIENTIFIC INDUSTRIES INC

Overview

Compare with Lifeloc Technologies, Inc, Accelerate Diagnostics or Seer, Inc, or pick any stock.

• TickerSCND on OTC¹
• IndustryLaboratory Analytical Instruments¹
• HeadquartersBohemia, New York¹
• Incorporated inDE²
• Business address70 Orville Dr, Airport International Plz, Bohemia, Ny 11716²
• Filer categoryNon-accelerated filer, Smaller reporting company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

General . Incorporated in 1954, Scientific Industries, Inc., a Delaware corporation (“SI” and along with its subsidiaries, the “Company”), is engaged in the design, manufacture, and marketing of standard benchtop laboratory equipment (“Benchtop Laboratory Equipment”), and through its wholly-owned subsidiary, Scientific Bioprocessing Holdings, Inc., a Delaware corporation (“SBHI”), the design, manufacture, and marketing of bioprocessing systems and products (“Bioprocessing Systems”). SBHI has two wholly-owned subsidiaries – Scientific Bioprocessing, Inc., a Delaware corporation (“SBI”), and aquila biolabs GmbH, a German corporation (“Aquila”). The Company’s products are used primarily for research purposes by universities, pharmaceutical companies, pharmacies, national laboratories, medical device manufacturers, and other industries performing laboratory-scale research. On August 7, 2025,…³ From its latest annual report

Corporate structure

SCIENTIFIC INDUSTRIES INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What SCIENTIFIC INDUSTRIES INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Intangibles and goodwill

Inventory

Properties, in its own words

The Company leases certain properties consisting principally of a facility in Bohemia, New York (headquarters) which was amended in September 2021 to increase the space by approximately 25% and extend the lease term through October 2028. The Company leased a 1,200 square foot facility in Orangeburg, New York where it conducted its sales and marketing functions, primarily for the Torbal® Products Division of the Benchtop Laboratory Equipment operations, which expired at the end of October 2024 and was not renewed and continued as a monthly lease through the end of December 31, 2024. On January 1, 2025, the Company entered into a lease for a 220 square foot facility in Pearl River, New York where it conducts its sales and marketing functions, primarily for the Torbal® Products Division of the Benchtop Laboratory Equipment operations, expiring in December 2027. The Company’s Bioprocessing Systems operations are conducted in co-sharing office space in Pittsburgh, Pennsylvania, which expired in March 2025 and is currently on a month-to-month basis, and a 5,252 square foot facility in Baesweiller, Germany, the lease which was renewed in December 2025 to extend the lease term to December 31, 2027, comprised of manufacturing, engineering, and administrative space

Item 2 of the 10-K filed Mar 31, 2026.³

Leadership

Who has led SCIENTIFIC INDUSTRIES INC, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerHelena R. Santos Jun 21, 2007 to now¹²
• ChairJohn A. Moore Jul 24, 2020 to now¹³
• PresidentKarl Nowosielski Sep 26, 2014 to Oct 4, 2017¹⁴
• PresidentBrookman Peter March Aug 27, 2012 to Aug 27, 2012¹⁵
• PresidentHelena R. Santos Jun 21, 2007 to Aug 27, 2012¹²
• Chief financial officerZachary Rovinsky Dec 29, 2025 to now¹⁶
• Chief financial officerReginald Averilla Jul 13, 2022 to Jul 1, 2024¹⁷

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerRobert Nichols named Mar 4, 2022³⁵
• DirectorChristopher Cox named Mar 4, 2022 to May 1, 2025³⁶
• DirectorJuergen Schumacher named Mar 4, 2022 to May 1, 2025³⁶
• DirectorReinhard Vogt named Mar 4, 2022³⁵

Timeline

1. Oct 2, 20268-K Entered a material agreement³⁷
2. Jan 20, 20268-K Change of auditor³⁸
3. Dec 5, 20258-K Entered a material agreement; Completed an acquisition or sale³⁹
4. Aug 27, 20258-K Change of auditor; Executive or director change⁴⁰
5. Aug 11, 20258-K Entered a material agreement; Completed an acquisition or sale⁴¹
6. May 21, 20258-K Entered a material agreement; Executive or director change⁴²
7. Apr 22, 20258-K Entered a material agreement; Unregistered sale of shares⁴³
8. Apr 2, 20258-K Executive or director change⁴⁴
9. Jun 6, 20248-K Change of auditor⁴⁵
10. Apr 15, 20248-K Executive or director change⁴⁶
11. Apr 8, 20248-K Executive or director change⁴⁷
12. Mar 7, 20248-K Executive or director change⁴⁸
13. Jun 21, 2007New chief executive Helena R. Santos becomes CEO¹²

Filings

198 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 32 major events, 73 insider forms, 28 large holders, 3 private raises, 40 other. The latest 20:

1. Oct 2, 20268-K EDGAR
2. Sep 8, 20264 PRIMARY DOCUMENT EDGAR
3. Aug 20, 20264 PRIMARY DOCUMENT EDGAR
4. Aug 14, 202610-Q EDGAR
5. Aug 13, 2026SCHEDULE 13G/A EDGAR
6. Jun 18, 20264 PRIMARY DOCUMENT EDGAR
7. May 15, 202610-Q EDGAR
8. Apr 1, 20264 PRIMARY DOCUMENT EDGAR
9. Apr 1, 20264 PRIMARY DOCUMENT EDGAR
10. Mar 31, 202610-K EDGAR
11. Mar 24, 20264 PRIMARY DOCUMENT EDGAR
12. Mar 17, 20264 PRIMARY DOCUMENT EDGAR
13. Mar 17, 20264 PRIMARY DOCUMENT EDGAR
14. Mar 17, 20264 PRIMARY DOCUMENT EDGAR
15. Mar 17, 20264 PRIMARY DOCUMENT EDGAR
16. Mar 17, 20264 PRIMARY DOCUMENT EDGAR
17. Jan 20, 20268-K EDGAR
18. Dec 29, 20253 PRIMARY DOCUMENT EDGAR
19. Dec 29, 2025DEF 14A EDGAR
20. Dec 18, 20254 PRIMARY DOCUMENT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

44 open-market trades by officers, directors and large owners since October 2021: 31 buys and 13 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Laurence W. LyttonSCHEDULE 13G/A, 6 filings Mar 30, 2022 to Aug 13, 2026⁴⁹
• Bleichroeder LPSCHEDULE 13D/A, 7 filings Feb 14, 2022 to Nov 14, 2025⁵⁰
• NORTH RUN CAPITAL, LPSCHEDULE 13G/A, 5 filings Feb 14, 2024 to Nov 13, 2025⁵¹
• Sandra F. PessinSCHEDULE 13D/A, 2 filings Apr 23, 2025 to Aug 22, 2025⁵²
• Thomas A. Satterfield Jr.SCHEDULE 13G/A, 4 filings Mar 23, 2022 to Feb 12, 2025⁵³
• Veradace Capital Management LLCSC 13D, 3 filings Feb 15, 2022 to Dec 29, 2023⁵⁴
• Roy T. EddlemanSC 13D/A, 1 filing Feb 15, 2023⁵⁵

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Apr 18, 2025Raised $1.6 million in a private offering of equity³⁶ Form D: 11 investors so far Form D
2. Dec 13, 2023Raised $7 million in a private offering of equity⁵⁶ Form D: 58 investors so far Form D
3. Mar 2, 2022Raised $3 million in a private offering of equity³⁵ Form D: 38 investors so far Form D

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA⁵⁷. Matched to this company by name and state.

1. Apr 14, 2020$563.7K PPP loan (first draw) from First National Bank of Pennsylvania⁵⁷To SCIENTIFIC INDUSTRIES INC, Bohemia NY; $537.6K forgiven Jun 17, 2021
2. Mar 12, 2021$433.8K PPP loan (second draw) from First National Bank of Pennsylvania⁵⁷To SCIENTIFIC INDUSTRIES INC., Bohemia NY; $436.8K forgiven Dec 1, 2021

SEC filer profile

How SCIENTIFIC INDUSTRIES INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARSCIENTIFIC INDUSTRIES INC¹
• CIK0000087802
• Employer ID (EIN)04-2217279³
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)3826 Laboratory Analytical Instruments¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address70 Orville Dr, Airport International Plz, Bohemia, NY 11716¹
• Mailing address70 Orville Dr, Bohemia, NY 11716¹
• Phone6315674700¹
• Shares outstanding11,928,599 as of Aug 13, 2026¹¹
• Public float$3.7M as of Jun 30, 2025³
• AuditorCarr, Riggs & Ingram L.L.C., Palm Beach Gardens, Florida PCAOB ID 213; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceNov 13, 1995¹
• Filings711 in all: 4 (224), 8-K (109), 10-Q (54), 10QSB (39), DEF 14A (27), DEFA14A (25), 3 (20), 10-K (17)¹
  All 43 form types

  SC 13G/A (16), 4/A (14), SC 13D/A (14), UPLOAD (14), 10KSB (13), CORRESP (11), S-1/A (11), SC 13G (11), SC 13D (9), 5 (6), 8-K/A (6), D (6), NT 10-Q (6), 10KSB/A (5), NT 10-K (5), S-1 (5), S-8 (5), SCHEDULE 13D/A (5), SCHEDULE 13G/A (5), 10QSB/A (4), 424B3 (4), EFFECT (4), 10-Q/A (3), DFAN14A (2), PRRN14A (2), 10-K/A (1), 10-KT (1), 5/A (1), ARS (1), DEFC14A (1), NTN 10K (1), PREC14A (1), PREM14A (1), RW (1), S-8 POS (1)

• Latest filingsAnnual report (10-K) Mar 31, 2026
  Quarterly report (10-Q) Aug 14, 2026
  Proxy statement (DEF 14A) Dec 29, 2025
  Latest 8-K (8-K) Oct 2, 2026

Risk factors and legal proceedings

The risks SCIENTIFIC INDUSTRIES INC names in Item 1A of its 10-K filed Mar 31, 2026: 21 risks under these headings, as written.³

• In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, important risk factors are identified below that could affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed with respect to such future periods in any current statements. The Company undertakes no obligation to publicly revise any forward-looking announcements to reflect future events or circumstances.
• Risks Relating to Our Financial Position and Capital Requirements
• We have limited financial resources and we may need to raise additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.
• Raising additional capital may cause dilution to our then-existing shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
• We have a history of Operating losses and will likely incur future losses during the next few years as we attempt to grow and develop our bioprocessing sector.
• If we fail to maintain proper and effective internal controls over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors’ views of us and, as a result, the value of our Common Stock.
• Limited public market for our common stock and active trading market may never develop or be sustained.
• Risks Relating to Our Business
• The commercial success of our bioprocessing products will largely depend upon attaining significant market acceptance.
• If we are unable to obtain and maintain patent and other intellectual property protection for any of our new bioprocessing products, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize any product we may develop may be adversely affected.
• If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
• If we lose the services of key management personnel, we may not be able to execute our business strategy effectively.

Legal proceedings

The Company is not a party to any pending legal proceedings.

The opening of Item 3, Legal Proceedings.³